The prevalence of nosocomial infection in intensive care units in Europe: results of the European Prevalence of Infection in Intensive Care (EPIC) Study, Jama, vol.274, issue.8, pp.639-644, 1995. ,
International study of the prevalence and outcomes of infection in intensive care units, Jama, vol.302, issue.21, pp.2323-2329, 2009. ,
Epidemiology of nosocomial fungal infections, with emphasis on Candida species, Clin Infect Dis, vol.20, issue.6, pp.1526-1530, 1995. ,
Population-Based Analysis of Invasive Fungal Infections, Emerg Infect Dis. juill, vol.20, issue.7, pp.1163-1172, 2001. ,
Invasive Candidiasis. Campion EW, éditeur, N Engl J Med, vol.373, issue.15, pp.1445-56, 2015. ,
Diagnosis and management of invasive candidiasis in the ICU: an updated approach to an old enemy. Crit Care (Internet). déc 2016 (cité 12 janv 2018), vol.20 ,
Antifungal de-escalation was not associated with adverse outcome in critically ill patients treated for invasive candidiasis: post hoc analyses of the AmarCAND2 study data, Intensive Care Med. nov, vol.41, issue.11, pp.1931-1971, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01205360
Worrisome trends in incidence and mortality of candidemia in intensive care units, Intensive Care Med. sept, vol.40, issue.9, pp.1303-1315, 2002. ,
URL : https://hal.archives-ouvertes.fr/pasteur-01405246
Incidence and mortality of sepsis, severe sepsis, and septic shock in intensive care unit patients with candidemia, Infect Dis. 3 août, vol.47, issue.8, pp.584-591, 2015. ,
The changing epidemiology of healthcare-associated candidemia over three decades, Diagn Microbiol Infect Dis. mai, vol.73, issue.1, pp.45-53, 2012. ,
Epidemiology and predictive factors for early and late mortality in Candida bloodstream infections: a population-based surveillance in Spain, Clin Microbiol Infect. avr, vol.20, issue.4, pp.245-54, 2014. ,
Trends in mortality due to invasive mycotic diseases in the United States, Clin Infect Dis, vol.33, issue.5, pp.641-647, 1980. ,
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem, Clin Microbiol Rev. 1 janv, vol.20, issue.1, pp.133-63, 2007. ,
Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: A multicenter, prospective, observational study in France, Crit Care Med. mai, vol.37, issue.5, pp.1612-1620, 2005. ,
URL : https://hal.archives-ouvertes.fr/hal-00676899
Impact of Treatment Strategy on Outcomes in Patients with Candidemia and Other Forms of Invasive Candidiasis: A Patient-Level Quantitative Review of Randomized Trials, Clin Infect Dis. 15 avr, vol.54, issue.8, pp.1110-1132, 2012. ,
Candida colonization and subsequent infections in critically ill surgical patients, Ann Surg. déc, vol.220, issue.6, pp.751-759, 1994. ,
A bedside scoring system (« Candida score ») for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization, Crit Care Med. mars, vol.34, issue.3, pp.730-737, 2006. ,
Can yeast isolation in peritoneal fluid be predicted in intensive care unit patients with peritonitis?*: Crit Care Med, mars, vol.31, issue.3, pp.752-759, 2003. ,
The germ tubes of Candida albicans hyphae and pseudohyphae show different patterns of septin ring localization, Mol Microbiol. juill, vol.41, issue.1, pp.19-31, 2001. ,
Physiopathologie des candidoses invasives, Réanimation. mai, vol.24, issue.3, pp.318-345, 2015. ,
Genetic control of Candida albicans biofilm development, Nat Rev Microbiol. févr, vol.9, issue.2, pp.109-127, 2011. ,
Severe Sepsis and Septic Shock, N Engl J Med. 29 août, vol.369, issue.9, pp.840-51, 2013. ,
Epidemiology of Candida species infections in critically ill non-immunosuppressed patients, Lancet Infect Dis, vol.3, issue.11, pp.685-702, 2003. ,
Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America, Clin Infect Dis. 16 déc, p.933, 2015. ,
Candida bloodstream infections in intensive care units: Analysis of the extended prevalence of infection in intensive care unit study*: Crit Care Med, avr, vol.39, issue.4, pp.665-70, 2011. ,
Prognostic factors and historical trends in the epidemiology of candidemia in critically ill patients: an analysis of five multicenter studies sequentially conducted over a 9-year period, Intensive Care Med, vol.40, issue.10, pp.1489-98, 2014. ,
Epidemiology and outcomes of candidemia in 3648 patients: data from the Prospective Antifungal Therapy (PATH Alliance®) registry, Diagn Microbiol Infect Dis. déc, vol.74, issue.4, pp.323-354, 2004. ,
Epidemiology and Predictors of Mortality in Cases of Candida Bloodstream Infection: Results from Population-Based Surveillance, J Clin Microbiol. 1 avr, vol.43, issue.4, pp.1829-1864, 2002. ,
Impact on hospital mortality of catheter removal and adequate antifungal therapy in Candida spp. bloodstream infections, J Antimicrob Chemother. 1 janv, vol.68, issue.1, pp.206-219, 2013. ,
Septic Shock Attributed to Candida Infection: Importance of Empiric Therapy and Source Control, Clin Infect Dis. 15 juin, vol.54, issue.12, pp.1739-1785, 2012. ,
The Epidemiology and Attributable Outcomes of Candidemia in Adults and Children Hospitalized in the United States: A Propensity Analysis, Clin Infect Dis, vol.41, issue.9, pp.1232-1241, 2005. ,
Echinocandins in the treatment of candidaemia and invasive candidiasis: clinical and economic perspectives, Int J Antimicrob Agents. mars, vol.43, issue.3, pp.207-221, 2014. ,
A research agenda on the management of intra-abdominal candidiasis: results from a consensus of multinational experts, Intensive Care Med. déc, vol.39, issue.12, pp.2092-106, 2013. ,
Clinical and microbiological profiles of community-acquired and nosocomial intra-abdominal infections: results of the French prospective, observational EBIIA study, J Antimicrob Chemother. avr, vol.63, issue.4, pp.785-94, 2009. ,
Candida peritonitis due to peptic ulcer perforation: incidence rate, risk factors, prognosis and susceptibility to fluconazole and amphotericin B, Diagn Microbiol Infect Dis. sept, vol.44, issue.1, pp.23-30, 2002. ,
The epidemiology of intraabdominal flora in critically ill patients with secondary and tertiary abdominal sepsis, Infection. déc, vol.37, issue.6, pp.522-529, 2009. ,
Tertiary Peritonitis: Clinical Features of a Complex Nosocomial Infection, World J Surg. 1 févr, vol.22, issue.2, pp.158-63, 1998. ,
Identification of Patients at Risk for Development of Tertiary Peritonitis on a Surgical Intensive Care Unit, J Gastrointest Surg. juill, vol.13, issue.7, pp.1358-67, 2009. ,
A multicentre study of antifungal strategies and outcome of Candida spp. peritonitis in intensive-care units, Clin Microbiol Infect. juill, vol.17, issue.7, pp.1061-1068, 2011. ,
URL : https://hal.archives-ouvertes.fr/hal-00874787
A multicenter multinational study of abdominal candidiasis: epidemiology, outcomes and predictors of mortality, Intensive Care Med. sept, vol.41, issue.9, pp.1601-1611, 2015. ,
Candida as a risk factor for mortality in peritonitis*, Crit Care Med. mars, vol.34, issue.3, pp.646-52, 2006. ,
Predictive Factors of Mortality Due to Polymicrobial Peritonitis With Candida Isolation in Peritoneal Fluid in Critically Ill Patients, Arch Surg. 1 déc, vol.137, issue.12, p.1341, 2002. ,
Factors associated with septic shock and mortality in generalized peritonitis: comparison between community-acquired and postoperative peritonitis, Crit Care, vol.13, issue.3, p.99, 2009. ,
Suspicion de péritonite à Candida dans l'étude AMARCAND II : peut-on prédire les patients qui vont avoir une culture positive ?, Anesth Réanimation. sept, vol.1, pp.215-221, 2015. ,
Can yeast isolation be predicted in complicated secondary non-postoperative intra-abdominal infections?, Crit Care Lond Engl. 27 févr, vol.19, p.60, 2015. ,
Résistance des Candida aux antifongiques : détection et mécanismes, Rev Francoph Lab. mars, vol.2013, issue.450, pp.71-78, 2013. ,
Systemic antifungal therapy in critically ill patients without invasive fungal infection*, Crit Care Med. mars, vol.40, issue.3, pp.813-835, 2012. ,
Traitements antifongiques en réanimation au cours des infections fongiques invasives documentées ou suspectées, Ann Fr Anesth Réanimation. avr, vol.33, issue.4, pp.232-241, 2014. ,
Antifungal drug resistance mechanisms in fungal pathogens from the perspective of transcriptional gene regulation, FEMS Yeast Res, vol.9, issue.7, pp.1029-50, 2009. ,
Screening for amino acid substitutions in the Candida albicans Erg11 protein of azole-susceptible and azole-resistant clinical isolates: new substitutions and a review of the literature, Diagn Microbiol Infect Dis. avr, vol.66, issue.4, pp.373-84, 2010. ,
Efflux-Mediated Antifungal Drug Resistance, Clin Microbiol Rev. 1 avr, vol.22, issue.2, pp.291-321, 2009. ,
Resistance to echinocandin-class antifungal drugs, Drug Resist Updat. juin, vol.10, issue.3, pp.121-151, 2007. ,
Methods for studying the in vitro susceptibility of Candida spp. to antifungals, Ann Biol Clin, issue.6, pp.635-642 ,
Résistance de Candida spp. aux antifongiques, 2014. ,
Wild-Type MIC Distributions and Epidemiological Cutoff Values for Amphotericin B, Flucytosine, and Itraconazole and Candida spp. as Determined by CLSI Broth Microdilution, J Clin Microbiol. juin, vol.50, issue.6, pp.2040-2046, 2012. ,
Clinical and Laboratory Standards Institute, éditeurs. Reference method for broth dilution antifungal susceptibility testing of yeasts: approved standard, 2008. ,
EUCAST technical note on the EUCAST definitive document EDef 7.2: method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts EDef 7.2 (EUCAST-AFST)*, Clin Microbiol Infect. juill, vol.18, issue.7, pp.246-253, 2012. ,
Clinical and Laboratory Standards Institute. Performance standards for antifungal susceptibility testing of yeasts, 2017. ,
Candidémies en Île-de-France : données de l'Observatoire des levures, p.4, 2002. ,
A Risk Score for Fluconazole Failure among Patients with Candidemia, Antimicrob Agents Chemother. mai, vol.61, issue.5, pp.2091-2107, 2017. ,
A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study, JAMA. 22 déc, vol.270, issue.24, pp.2957-63, 1993. ,
APACHE II: a severity of disease classification system, Crit Care Med. oct, vol.13, issue.10, pp.818-847, 1985. ,
Sepsis in European intensive care units: Results of the SOAP study*, Crit Care Med. févr, vol.34, issue.2, pp.344-53, 2006. ,
Charlson comorbidity index as a predictor of outcomes in incident peritoneal dialysis patients, Am J Kidney Dis Off J Natl Kidney Found. févr, vol.37, issue.2, pp.337-379, 2001. ,
Clinical breakpoints for the echinocandins and Candida revisited: Integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria, Drug Resist Updat. juin, vol.14, issue.3, pp.164-76, 2011. ,
Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of speciesspecific interpretive criteria, Diagn Microbiol Infect Dis. juill, vol.70, issue.3, pp.330-373, 2011. ,
Epidemiology and Outcomes of Candidemia in 2019 Patients: Data from the Prospective Antifungal Therapy Alliance Registry, Clin Infect Dis. 15 juin, vol.48, issue.12, pp.1695-703, 2009. ,
Presentation of the PATH Alliance® registry for prospective data collection and analysis of the epidemiology, therapy, and outcomes of invasive fungal infections, Diagn Microbiol Infect Dis. déc, vol.59, issue.4, pp.407-421, 2007. ,
Épidémiologie des candidoses invasives en France, Réanimation. mai, vol.25, issue.S2, pp.37-43, 2016. ,
, Réseau ATB Raisin Résultats, p.109, 2012.
, Réseau ATB Raisin Résultats, p.116, 2013.
, Amiens Introduction: la Candidose Invasive (CI) est une infection grave dont l'incidence augmente chez les patients immunodéprimés ou en réanimation malgré l'amélioration de leur prise en charge. L'objectif de cette étude était d'abord de comparer les patients présentant une CANDidémie (CAND), une Péritonite à Candida (PC) ou une CI d'Autre Localisation (AL), Résumé Epidémiologie des infections invasives à Candida, la consommation d'antifongiques et son impact sur la résistance au Centre Hospitalier Universitaire d
, Le recueil de données a porté sur la démographie, les scores de gravité, l'évolution clinique, la résistance des germes, les antifongiques et leur consommation annuelle entre, Méthodologie: une étude épidémiologique monocentrique rétrospective a été réalisée pour tous les patients ayant eu un prélèvement profond positif à Candida au CHU d'Amiens de janvier 2010 à décembre 2015, 2012.
, 0%) une AL. 60% des 875 souches étaient des C.Albicans, 14,1% des C.glabrata, 7,9% des C.tropicalis, 5,9% des C.Parapsilosis, 3,3% des C.krusei et 8,8% appartenaient à d'autres espèces. La répartition des germes ne variait pas selon les années (p=0,742). Les CAND étaient associées à 100 (48,1%) décès contre 128 (29,1%) dans les PC et 27 (34,2%) pour les AL (p=0,002). La survie était meilleure avec un traitement adapté (p=0,020), Résultats: 727 patients ont été inclus: 208 (28,6%) avaient une CAND, 440 (60,4%) une PC et 79, vol.3, p.0
, Conclusion: La CI reste associée à un pronostic vital défavorable. La candidémie, l'absence de traitement, la gravité initiale et les comorbidités sont associées à une plus grande mortalité. La consommation croissante d'antifongiques semble associée à une augmentation des résistances
, Abstract Epidemiology of invasive Candida infections, the consumption of antifungals and its impact on resistance at the Amiens University Hospital Center Introduction: Invasive Candidiasis (IC) is a serious infection with on increasing incidence in immunocompromised or intensive care despite improved management. The objective of this study was first to compare patients with CANDidemia (CAND), Candida Peritonitis (CP) or an IC of Other Localization (OL), Mots clés: Epidémiologie, candidémie, péritonite à levures, mortalité, complications, antifongique, résistance
, Methodology: A retrospective monocentric epidemiological study was carried out for all patients who had a deep positive Candida sampling at the CHU Amiens from, 2010.
, 4%) had a CP, and 79 (11.0%) had OL. 60% of the 875 strains were C.Albicans, 14.1% C.Glabrata, 7.9% C.Tropicalis, 5.9% C.Parapsilosis, 3.3% C.Krusei and 8.8 % belonged to other species. Spread distribution did not vary by year (p = 0.742). CANDs were associated with 100 (48.1%) deaths compared to 128 (29.1%) in the CP and 27 (34.2%) for the OL (p = 0.002). Survival was better with appropriate treatment, p.440